Ixoberogene soroparvovec

索哌艾基

Report date: 2026/03/20 20:03:07

Base Information

Drug NameIxoberogene soroparvovec
Drug Alias NameIxo-vecAAV.7m8-afliberceptADVM-022
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionGene transferenceVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesWeill Cornell Medical College
China Registration ClassN/A

Develop Information

Active CompaniesAdverum Biotechnologies Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A